CRSP
CRISPR Therapeutics AG
NASDAQ · Healthcare · Biotechnology · CH
$51.78
+3.57%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 25.2M | 3.5M | 35.0M | 370.0M | 436.0K |
| Cost of Revenue | 296.9M | 233.0M | 110.3M | 130.3M | 110.3M |
| Gross Profit | (271.7M) | (229.4M) | (75.3M) | 239.8M | (109.8M) |
| Operating Expenses | |||||
| R&D Expense | 283.3M | 265.3M | 320.7M | 387.3M | 461.6M |
| SG&A Expense | 68.9M | 73.5M | 73.0M | 76.2M | 102.5M |
| General & Admin Expense | 53.4M | 73.5M | 73.0M | 76.2M | 102.5M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 37.0M | — | (2.3M) | (1.2M) | (762.0K) |
| Total Operating Expenses | 389.2M | 338.9M | 391.3M | 462.3M | 563.3M |
| Cost and Expenses | 555.0M | 571.8M | 501.6M | 592.5M | 673.6M |
| Operating Income (EBIT) | (529.9M) | (568.3M) | (466.6M) | (222.5M) | (673.2M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | 76.2M | (9.6M) | 103.9M | 71.8M | 22.7M |
| Non-Operating Income (excl Interest) | (51.6M) | 9.6M | (103.9M) | (71.8M) | (22.7M) |
| EBT (Pre-Tax Income) | (453.6M) | (578.0M) | (362.7M) | (150.7M) | (650.5M) |
| Income Tax Expense | 2.5M | 3.6M | 3.6M | 2.9M | (325.0K) |
| Bottom Line | |||||
| Net Income | (456.1M) | (581.6M) | (366.3M) | (153.6M) | (650.2M) |
| Earnings from Cont. Ops | (456.1M) | (581.6M) | (366.3M) | (153.6M) | (650.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (456.1M) | (581.6M) | (366.3M) | (153.6M) | (650.2M) |
| Per Share | |||||
| Basic EPS | ($4.74) | ($6.47) | ($4.34) | ($1.94) | ($8.36) |
| Diluted EPS | ($4.74) | ($6.47) | ($4.34) | ($1.94) | ($8.36) |
| Revenue Per Share | $0.26 | $0.04 | $0.41 | $4.67 | $0.01 |
| Shares | |||||
| Basic Shares Outstanding | 96.7M | 89.9M | 84.4M | 79.2M | 77.7M |
| Diluted Shares Outstanding | 96.7M | 89.9M | 84.4M | 79.2M | 77.7M |
| Profitability Metrics | |||||
| EBITDA | (459.8M) | (558.5M) | (343.4M) | (130.9M) | (626.3M) |
| D&A | 18.5M | 19.5M | 19.3M | 19.8M | 24.2M |
| EBIT | (478.3M) | (578.0M) | (362.7M) | (150.7M) | (650.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026